Body surface area-dosing does not account for the complex processes of cytotoxic drug elimination. This leads to an unpredictable variation in effect. Overdosing is easily recognised but it is ...

How many of us give a “full” dose of chemotherapy to an obese patient—even in the curative setting? Dose calculation in the obese is a confusing but important puzzle for the oncologist and is becoming ...

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. The current investigation focused on the effects of different ...